<DOC>
	<DOCNO>NCT00677287</DOCNO>
	<brief_summary>The purpose study evaluate safety time progression HLA-A*2402 restrict epitope peptide RNF43 , TOMM34 , VEGFR1 VEGFR2 emulsify Montanide ISA 51 combination Tegafur/Uracil/Folinate chemotherapy .</brief_summary>
	<brief_title>Histocompatibility Leukocyte Antigen ( HLA ) -A*2402 Restricted Peptide Vaccine Therapy Patients With Colorectal Cancer</brief_title>
	<detailed_description>RNF43 TOMM34 identify cancer specific molecule especially colorectal cancer use genome-wide expression profile analysis cDNA microarray technique . VEGF receptor 1 2 essential target tumor angiogenesis , identify peptide derive receptor significantly induce effective tumor specific CTL response vitro vivo . According finding , trial , evaluate safety , immunological clinical response peptide . Patients vaccinate twice week 8 week . On vaccination day , RNF43 peptide ( 1mg ) , TOMM34 peptide ( 1mg ) , VEGFR1 peptide ( 1mg ) VEGFR2 peptide ( 1mg ) mixed Montanide ISA 51 administer subcutaneous injection . The patient also receive oral chemotherapy ( Tegafur/Uracil/Folinate ) simultaneously . Repeated cycle vaccine chemotherapy administer patient develop progressive disease unacceptable toxicity , whichever occur first . In phase I study , evaluate safety tolerability peptide vaccine . In follow phase II study , evaluate immunological clinical response vaccine therapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Advanced recurrent colorectal cancer Resistant chemotherapy include CPT11 , lOHP„ÄÅ+/ 5FU +/ bevacizumab difficult continue chemotherapy due intolerable side effect ( ) ECOG performance status 02 Life expectancy &gt; 3 month HLAA*2402 Laboratory value follow 2000/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 100000/mm3 Bilirubin &lt; 3.0mg/dl Asparate transaminase &lt; 150IU/L Alanine transaminase &lt; 150IU/L Creatinine &lt; 3.0mg/dl Able receive oral Tegafur/Uracil/Folinate therapy Able willing give valid write informed consent Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeding Active uncontrolled infection Unhealed external wound Concurrent treatment steroid immunosuppressing agent Prior chemotherapy , radiation therapy , immunotherapy within 4 week Uncontrolled brain and/or intraspinal lesion ( ) History allergy Tegafur , Uracil , and/or Folinate Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>HLA-A*2402</keyword>
	<keyword>Peptide Vaccine</keyword>
	<keyword>RNF43</keyword>
	<keyword>TOMM34</keyword>
	<keyword>VEGFR1</keyword>
	<keyword>VEGFR2</keyword>
</DOC>